RecruitingPhase 2 / Phase 3NCT06996730
Rare condition
Early-onset autosomal dominant Alzheimer disease
3
studies recruiting now
as of 7 Sept 2026
9
studies registered in total
as of 7 Sept 2026
15
countries with a recruiting site
as of 7 Sept 2026
30 May 2025
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 2 / Phase 3NCT06647498
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RecruitingPhase 2 / Phase 3NCT05552157
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Showing the 3 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
Search all Early-onset autosomal dominant Alzheimer disease studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Early-onset autosomal dominant Alzheimer disease study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Early-onset autosomal dominant Alzheimer disease
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the genes involved (TREM2, PSEN1, PSEN2, APP, SORL1, TOMM40).
Treatments being studied
27 approved treatments and 316 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Berotralstat Hydrochloride (Orladeyo)Approved: Flortaucipir F 18 (Tauvid)Approved: Memantine Hydrochloride (Akatinol)Approved: Ergoloid Mesylates (Alkergot)Approved: Donanemab (Kisunla)Approved: Gv-971Approved: Galantamine (Acumor xl)Approved: Aducanumab (Aduhelm)Approved: Human Immunoglobulin G (Flebogamma dif (previously flebogammadif))Approved: ThiazolidinedioneApproved: Lisdexamfetamine Dimesylate (Elvanse)Approved: MemantineApproved: DonepezilApproved: Guanfacine Hydrochloride (Akfen)Approved: Donepezil Hydrochloride (Adlarity)Approved: Rivastigmine (Exelon)Approved: Atomoxetine Hydrochloride (Atomoxetine hydrochloride)Approved: Florbetaben F18 (Neuraceq)Approved: Lecanemab (Leqembi)Approved: Rivastigmine Tartrate (Exelon)Approved: Flutemetamol F 18 (Vizamyl)Approved: Ioflupane I 123 (Celsunax)Approved: Huperzine AApproved: Methylphenidate Hydrochloride (Adhansia xr)Approved: Florbetapir F 18 (Amyvid)Approved: TacrineApproved: Galantamine Hydrobromide (Galantamine hydrobromide)
Phase 3Caffeine (Caffeine component of anoquan)
Phase 3Brexpiprazole (Rexulti)
Phase 3Solanezumab
Phase 3Crenezumab
Phase 3Florzolotau (18f)
Phase 3Bifeprunox
Phase 3Semagacestat
Phase 3Hydromethylthionine Mesylate (Lmtx)
+ 308 more in development
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).